R
Rakesh K. Jain
Researcher at Harvard University
Publications - 1528
Citations - 198912
Rakesh K. Jain is an academic researcher from Harvard University. The author has contributed to research in topics: Angiogenesis & Cancer. The author has an hindex of 200, co-authored 1467 publications receiving 177727 citations. Previous affiliations of Rakesh K. Jain include Government Medical College, Thiruvananthapuram & University of Oslo.
Papers
More filters
Patent
Semiconductor structure with inhomogeneous regions
Maxim S. Shatalov,Alexander Dobrinsky,Alexander Lunev,Rakesh K. Jain,Jinwei Yang,Michael Shur,Remigijus Gaska +6 more
TL;DR: In this article, a semiconductor layer including a plurality of inhomogeneous regions is provided, each region has one or more attributes that differ from a material forming the semiconductor layers.
Journal ArticleDOI
Methyl 3,4-0-isopropylidene-2-O-(4-methoxybenzyl)-1-thio-β-L-fucopyranoside — a novel, efficient glycosylating reagent for the synthesis of linear and other α-L-fucosyl oligosaccharides
Rakesh K. Jain,Khushi L. Matta +1 more
TL;DR: In this article, a facile approach for the synthesis of linear L-fucosyloligosaccharides containing α-L-(1»2) interglycosidic linkages was made possible through the development and utilization of the titled glycosylating reagent.
Journal ArticleDOI
Arthrobacter nitrophenolicus sp. nov. a new 2-chloro-4-nitrophenol degrading bacterium isolated from contaminated soil.
TL;DR: Strain SJConT, a 2-chloro-4-nitrophenol (2C4NP) degrading bacterium, was isolated from soil collected from a pesticide-contaminated site in Punjab, India, and showed morphological and chemotaxonomic properties consistent with those reported for members of the genus Arthrobacter.
Journal ArticleDOI
Expression of blood group Lewis b determinant from Lewis a: association of this novel alpha (1,2)-L-fucosylating activity with the Lewis type alpha (1,3/4)-L-fucosyltransferase.
E. V. Chandrasekaran,Rakesh K. Jain,John Rhodes,Cheryl A. Srnka,Robert D. Larsen,Khushi L. Matta +5 more
TL;DR: The present study demonstrates the association of this new type of alpha (1,2)- L-fucosyltransferase (FT) activity with the Lewis-type alpha ( 1,3/4)-L-FT, which was highly effective in fucOSylating complex glycopeptides.
Journal ArticleDOI
Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma
Neil S. Horowitz,Richard T. Penson,Dan G. Duda,Emmanuelle di Tomaso,Yves Boucher,Marek Ancukiewicz,Kenneth S. Cohen,Suzanne Berlin,Carolyn N. Krasner,Marsha A. Moses,Rakesh K. Jain +10 more
TL;DR: Biomarker evaluations showed that bevacizumab with chemotherapy significantly changed the levels of several circulating cellular and molecular biomarkers and increases in plasma PlGF and VEGFR2(+) monocytes showed correlations with outcome.